Skip to main content

Table 1 Patients characteristics

From: Feasibility study of first-line chemotherapy using Pemetrexed and Bevacizumab for advanced or recurrent nonsquamous non-small cell lung cancer in elderly patients: TORG1015

Male/Female

6/6

Age median (range)

78 (72–81)

 <75/≥75

1/11

ECOG PS 0/1

6/6

Smoking (Current/former/never)

1/5/6

Stage IIIB/IV/Recurrent disease

2/8/2

Histology (adenocarcinoma/others)

12/0

Activating EGFR mutation (No/Yes/Unknown)

9/2/1

  1. ECOG Eastern cooperative Oncology Group, PS performance status